KR910021375A - 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈[cd]인돌의 결정형 염 - Google Patents

4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈[cd]인돌의 결정형 염 Download PDF

Info

Publication number
KR910021375A
KR910021375A KR1019910003029A KR910003029A KR910021375A KR 910021375 A KR910021375 A KR 910021375A KR 1019910003029 A KR1019910003029 A KR 1019910003029A KR 910003029 A KR910003029 A KR 910003029A KR 910021375 A KR910021375 A KR 910021375A
Authority
KR
South Korea
Prior art keywords
tetrahydrobenz
aminocarbonyl
propyl
amino
indole
Prior art date
Application number
KR1019910003029A
Other languages
English (en)
Other versions
KR100208114B1 (ko
Inventor
죠셉 크레스 토마스
리 배리 데이비드
Original Assignee
원본미기재
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 일라이 릴리 앤드 캄파니 filed Critical 원본미기재
Publication of KR910021375A publication Critical patent/KR910021375A/ko
Application granted granted Critical
Publication of KR100208114B1 publication Critical patent/KR100208114B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

4-(디--프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈[cd]인돌의 결정형 염
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 4-(디--프로필)아미노-6-아미노카보닐-1, 3, 4, 5-테트라하이드로벤즈(cd)인돌 히푸르산염.
  2. 제1항에 있어서, 실질적으로(4R)-4 -(디--프로필)아미노-6-아미노카보닐-1, 3, 4, 5-테트라하이드로벤즈(cd)인돌 히푸르산염인 화합물.
  3. 활성성분으로서 제1항 또는 제2항의 화합물과 함께 하나이상의 약학적으로 허용되는 부형제, 희석제또는 담체를 포함하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910003029A 1990-02-26 1991-02-25 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염 KR100208114B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48518590A 1990-02-26 1990-02-26
US7/485185 1990-02-26
US07/485185 1990-02-26

Publications (2)

Publication Number Publication Date
KR910021375A true KR910021375A (ko) 1991-12-20
KR100208114B1 KR100208114B1 (ko) 1999-07-15

Family

ID=23927224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910003029A KR100208114B1 (ko) 1990-02-26 1991-02-25 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염

Country Status (28)

Country Link
US (1) US5397799A (ko)
EP (1) EP0444852B1 (ko)
JP (1) JP3157007B2 (ko)
KR (1) KR100208114B1 (ko)
CN (1) CN1027503C (ko)
AT (1) ATE126506T1 (ko)
AU (1) AU629453B2 (ko)
BR (1) BR9100767A (ko)
CA (1) CA2037099C (ko)
CY (1) CY1887A (ko)
DE (1) DE69112099T2 (ko)
DK (1) DK0444852T3 (ko)
ES (1) ES2077796T3 (ko)
FI (1) FI95464C (ko)
GR (1) GR3017940T3 (ko)
HK (1) HK175495A (ko)
HU (1) HU217118B (ko)
IE (1) IE67801B1 (ko)
IL (1) IL97306A (ko)
LV (1) LV10251B (ko)
NO (1) NO174149C (ko)
NZ (1) NZ237181A (ko)
PT (1) PT96852B (ko)
RU (2) RU2034837C1 (ko)
SG (1) SG69975A1 (ko)
TW (1) TW219933B (ko)
YU (1) YU47594B (ko)
ZA (1) ZA911258B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
IL97308A (en) * 1990-02-26 1996-10-31 Lilly Co Eli Xahydrobenz [DC] Induced indoles in position 6, their preparation process and pharmaceutical preparations containing them
IL97309A (en) * 1990-02-26 1996-11-14 Lilly Co Eli Intermediates for hexahydrobenz] [DC indoles and a process for making their pure enantiomers
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5665744A (en) * 1991-03-28 1997-09-09 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenzn [cd] indoles
TW248556B (ko) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
EP3026044B8 (en) 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
EP2496084B1 (en) 2009-11-06 2015-06-10 Aerpio Therapeutics Inc. Compositions and methods for treating colitis
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (ko) 2011-06-06 2018-03-17
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles

Also Published As

Publication number Publication date
IE910625A1 (en) 1991-08-28
IL97306A0 (en) 1992-05-25
FI910895A0 (fi) 1991-02-25
HK175495A (en) 1995-11-24
GR3017940T3 (en) 1996-02-29
JP3157007B2 (ja) 2001-04-16
AU7197191A (en) 1991-08-29
KR100208114B1 (ko) 1999-07-15
CN1027503C (zh) 1995-01-25
FI95464B (fi) 1995-10-31
FI95464C (fi) 1996-02-12
EP0444852A3 (en) 1992-02-19
HUT56542A (en) 1991-09-30
RU2034837C1 (ru) 1995-05-10
RU2083561C1 (ru) 1997-07-10
DK0444852T3 (da) 1995-12-11
YU47594B (sh) 1995-10-24
CY1887A (en) 1996-04-05
FI910895A (fi) 1991-08-27
ES2077796T3 (es) 1995-12-01
YU32791A (sh) 1994-01-20
DE69112099T2 (de) 1996-02-08
HU217118B (hu) 1999-11-29
TW219933B (ko) 1994-02-01
ATE126506T1 (de) 1995-09-15
NO174149B (no) 1993-12-13
IL97306A (en) 1996-10-16
NZ237181A (en) 1992-06-25
CA2037099C (en) 2001-09-11
CA2037099A1 (en) 1991-08-27
SG69975A1 (en) 2000-01-25
LV10251A (lv) 1994-10-20
NO174149C (no) 1994-03-23
EP0444852B1 (en) 1995-08-16
PT96852B (pt) 1998-07-31
BR9100767A (pt) 1991-10-29
IE67801B1 (en) 1996-05-01
PT96852A (pt) 1991-10-31
AU629453B2 (en) 1992-10-01
CN1054589A (zh) 1991-09-18
US5397799A (en) 1995-03-14
LV10251B (en) 1995-04-20
EP0444852A2 (en) 1991-09-04
JPH04217662A (ja) 1992-08-07
NO910735L (no) 1991-08-27
NO910735D0 (no) 1991-02-25
DE69112099D1 (de) 1995-09-21
ZA911258B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
KR910021375A (ko) 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈[cd]인돌의 결정형 염
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
KR920002596A (ko) 아지비사이클로 유도체
KR950010892A (ko) 자궁 섬유증 억제 방법
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
ES2140652T3 (es) Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.
NO923721D0 (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
KR927003525A (ko) 술폰아닐리드 유도체 및 의약
DE68923169D1 (de) Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR910021374A (ko) 헥사하이드로 벤즈[cd]인돌
PT91203A (pt) Processo para a preparacao de novos derivados de antibioticos bu-3608 e de composicoes farmaceuticas que os contem
KR880013927A (ko) 피리미딘 유도체
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
ES2162856T3 (es) Derivados de ergolina serotoninergicos.
IL93594A0 (en) Pharmaceutical compositions containing an imidazopyrimidone derivative
ES2084771T3 (es) Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
AU1643592A (en) Novel compound and use of the same as medicine
KR920703050A (ko) 골형성 촉진제
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
KR910009257A (ko) 이펜프로딜 및 그의 유도체를 유효성분으로 하는 정신병치료제
KR890012960A (ko) 결정성 β-락탐 용매화물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060331

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee